Minireview
British Journal of Cancer (2006) 94, 341–345. doi:10.1038/sj.bjc.6602951 www.bjcancer.com
Published online 17 January 2006
The telomeric PARP, tankyrases, as targets for cancer therapy
H Seimiya1
1Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan
Correspondence: Dr H Seimiya, E-mail: hseimiya@jfcr.or.jp
Received 14 October 2005; Revised 12 December 2005; Accepted 19 December 2005; Published online 17 January 2006.
Abstract
The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1 modulates telomerase inhibition in human cancer cells and is reviewed in this report as a potential telomere-directed anticancer target.
Keywords:
tankyrase, poly(ADP-ribosyl)ation, telomeres, telomerase
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
At the end of the millennium, a view of the end
Nature Genetics News and Views (01 Dec 1999)
